ONL Therapeutics gets FDA orphan drug designation for ONL1204 to treat retinal detachment
ONL1204 is a novel, first-in-class small molecule peptide designed to protect key retinal cells, including photoreceptors, from cell death that occurs in a range of retinal diseases and